Login to Your Account

Pact for Eylea SR with Regeneron Pharma brings Ocular upside at back end

By Randy Osborne
Staff Writer

Thursday, October 13, 2016

Ocular Therapeutix Inc.'s potential $315 million pact with Regeneron Pharmaceuticals Inc. brought no up-front payment and only $10 million upon the exercise of an option – a carefully considered move, said Chief Financial Officer Brad Smith.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription